Oncology Molecular Diagnostics Global Market Opportunities and Strategies to 2035

This report describes and explains the Oncology Molecular Diagnostics market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global oncology molecular diagnostics market reached a value of nearly $5.65 billion in 2025, having grown at a compound annual growth rate (CAGR) of 12% since 2020. The market is expected to grow from $5.65 billion in 2025 to $9.16 billion in 2030 at a rate of 10.2%. The market is then expected to grow at a CAGR of 9% from 2030 and reach $14.11 billion in 2035.

Growth in the historic period resulted from increasing demand for personalized and precision medicine, expansion of healthcare infrastructure, growing investments in cancer research and drug development and increasing adoption of biomarker-based testing. Factors that negatively affected growth in the historic period were shortage of skilled healthcare professionals and high cost of molecular diagnostic tests.

Going forward, favorable government initiatives and funding programs, rising global cancer incidence, increasing focus on early cancer detection and screening programs, expansion of targeted therapies and companion diagnostics will drive the growth. Factors that could hinder the growth of the oncology molecular diagnostics market in the future include limited reimbursement coverage, stringent and evolving regulatory requirements and impact of trade war and tariff.

Market trends for the oncology molecular diagnostics market include expansion of companion diagnostics and integrated genomic profiling ecosystems, advancement of comprehensive genomic profiling and integrated assay platforms, rising adoption of RNA-based liquid biopsy and multiomic profiling platforms and expansion of liquid biopsy-based comprehensive genomic profiling.

The oncology molecular diagnostics market is segmented by product into instruments, reagents, and other products. The reagents market was the largest segment of the oncology molecular diagnostics market segmented by product, accounting for 56.9% or $3.21 billion of the total in 2025. Going forward, the reagents segment is expected to be the fastest-growing segment in the oncology molecular diagnostics market segmented by product, at a CAGR of 10.7% during 2025-2030.

The oncology molecular diagnostics market is segmented by technology into polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectroscopy, transcription mediated amplification (TMA), and other technologies. The polymerase chain reaction (PCR) was the largest segment of the oncology molecular diagnostics market segmented by technology, accounting for 31.9% or $1.8 billion of the total in 2025. Going forward, the sequencing segment is expected to be the fastest-growing segment in the oncology molecular diagnostics market segmented by technology, at a CAGR of 15.8% during 2025-2030.

The oncology molecular diagnostics market is segmented by end user into hospitals, diagnostic centers, academic and research institutes, and other end users. The hospitals market was the largest segment of the oncology molecular diagnostics market segmented by end user, accounting for 40.1% or $2.26 billion of the total in 2025. Going forward, the diagnostic centers segment is expected to be the fastest-growing segment in the oncology molecular diagnostics market segmented by end user, at a CAGR of 11.2% during 2025-2030.

The global oncology molecular diagnostics market is concentrated, with large players operating in the market. The top 10 competitors in the market made up 41.95% of the total market in 2024. F. Hoffmann-La Roche AG was the largest competitor with a 5.08% share of the market, followed by Thermo Fisher Scientific Inc. with 4.95%, Illumina Inc. with 4.87%, Danaher Corp. with 4.76%, Abbott Laboratories with 4.23%, Siemens Healthcare AG with 4.21%, QIAGEN N.V. with 4.06%, Agilent Technologies with 3.34%, Becton Dickinson and Company with 3.25% and bioMérieux SA with 3.21%.

The top opportunities in the Oncology Molecular Diagnostics market segmented by service type will arise in the toxicology and safety assessment segment, which will gain $1.13 billion of global annual sales by 2030. The top opportunities in the Oncology Molecular Diagnostics market segmented by animal model will arise in the small animal model segment, which will gain $2.81 billion of global annual sales by 2030. The top opportunities in the Oncology Molecular Diagnostics market segmented by assay type will arise in the toxicology assay segment, which will gain $1.12 billion of global annual sales by 2030. The top opportunities in the Oncology Molecular Diagnostics market segmented by disease area will arise in the oncology segment, which will gain $1.4 billion of global annual sales by 2030. The Oncology Molecular Diagnostics market size will gain the most in the USA at $1.07 billion.

Player-adopted strategies in the Oncology Molecular Diagnostics market include focus on strengthening its business through strategic acquisitions and new launches.

Market trends for the oncology molecular diagnostics market include expansion of companion diagnostics and integrated genomic profiling ecosystems, advancement of comprehensive genomic profiling and integrated assay platforms, rising adoption of RNA-based liquid biopsy and multiomic profiling platforms and expansion of liquid biopsy-based comprehensive genomic profiling.

To take advantage of the opportunities, the analyst recommends the oncology molecular diagnostics companies to focus on integrated genomic profiling and collaborative precision oncology platforms, focus on scalable comprehensive genomic profiling platforms for oncology diagnostics, focus on multiomic integration in oncology molecular diagnostics, focus on liquid biopsy and ctDNA integration for precision oncology growth, expand in emerging markets, continue to focus on developed markets, focus on reagents in oncology molecular diagnostics, focus on value-based and reimbursement-linked pricing strategy, focus on digital-first clinical engagement and evidence-led promotion, focus on key opinion leader partnerships and scientific conference visibility and focus on strengthening people capability across diagnostic center networks.

This product will be delivered within 3-5 business days.